 Recent Acquisition of RNAi drug maker Dicerna by Novo Nordisk makes a case for eventual partnershipbuyout of Arbutus Biopharma. AB-729 has proven to work in treating patients with Hepatitis B with significant Hepatitis B surface antigen reduction alone. Four triple combinations studies have started or will be initiated soon. 